Acrivon Therapeutics advances ACR-7280, shows complete tumor regression in AML models; IND filing targeted for H1 2027

Acrivon Therapeutics is advancing ACR-7280, showing complete tumor regression in AML models, with an IND filing targeted for H1 2027.

Detected & updated continuously · Source: Nebula